Shattuck Labs, Inc. (STTK)

Shattuck Labs' stock has experienced significant positive movement in the past six months. Over the last 12 months, the stock price increased by 638.86%, with a 59.44% increase in the past month and a year-to-date return of 71.23% as of April 1, 2026. The stock traded at $6.43 with a market cap of $460.13 million as of April 1, 2026. Key events impacting the stock include the Q4 and Full-Year 2025 Earnings Report, the advancement of SL-325, the discontinuation of the SL-172154 Program, participation in investor conferences, and analyst coverage.

As a clinical-stage biotechnology company, Shattuck Labs, Inc. does not currently have commercialized products or services with traditional consumer demand seasonality. Its financial performance and stock price are more influenced by clinical trial progress, regulatory milestones, and financial results rather than seasonal fluctuations in product demand.

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing bi-functional fusion proteins as a novel class of biologic medicine, operating within the Health Technology sector, specifically in Drug Discovery. The company researches and develops potential treatments for inflammatory, immune-mediated diseases, and cancer, utilizing its proprietary ARC® and GADLEN™ platforms. Key product candidates include SL-325, a DR3 blocking monoclonal antibody in Phase 1 trials; SL-425, a half-life extended version of SL-325; DR3-based bispecific antibodies; TRIM7, an oncology-focused program; and SL-172154 (SIRPα-Fc-CD40L), which was discontinued in 2025.

Shattuck Labs, Inc. is headquartered in Austin, Texas, with R&D facilities in Durham, North Carolina. The company primarily serves the U.S. market and is preparing for broader geographic reach as its clinical programs advance. Shattuck Labs is incorporated in Delaware.

Shattuck Labs generally holds a positive brand reputation among analysts. The company has a consensus "Moderate Buy" rating from Wall Street analysts. Management's engagement with investors at various healthcare conferences also contributes to maintaining visibility and communication with the financial community. There is no readily available information indicating specific events that have negatively affected Shattuck Labs, Inc.'s brand reputation in the past year.

Shattuck Labs, Inc. has a diverse ownership structure, with institutional shareholders holding the largest portion. Approximately 58.73% of the company's stock is held by institutional shareholders, 20.75% by Shattuck Labs insiders, and 20.53% by retail investors. Major institutional owners include Adage Capital Partners GP LLC, Orbimed Advisors LLC, and Redmile Group LLC, among others.